The consumer-genomics company 23andMe just sold its biobank of customer genetic data to drugmaker Regeneron for $256 million.

Regeneron is to pay $256 million in cash to acquire “substantially all” of 23andMe’s assets, including its massive biobank of around 15 million customer genetic samples and data.

  • Didros@beehaw.org
    21·
    2 days ago

    Anyone trusting anyone else in a capitalist society is signing up to be the sucker. Has been this way for 200 years.

    Historically illiterate populace.